Helmut R Maecke
Radioimmunotherapy with 177Lu-DOTA-rituximab: final results of a phase I/II Study in 31 patients with relapsing follicular, mantle cell, and other indolent B-cell lymphomas
Forrer F, Oechslin-Oberholzer C, Campana B, Herrmann R, Maecke H, Mueller-Brand J, Lohri A. Radioimmunotherapy with 177Lu-DOTA-rituximab: final results of a phase I/II Study in 31 patients with relapsing follicular, mantle cell, and other indolent B-cell lymphomas. J Nucl Med 2013; 54:1045-52.
09.04.2013Radioimmunotherapy with 177Lu-DOTA-rituximab: final results of a phase I/II Study in 31 patients with relapsing follicular, mantle cell, and other indolent B-cell lymphomas
09.04.2013J Nucl Med 2013; 54:1045-52
Forrer Flavio, Oechslin-Oberholzer Catharina, Campana Benedetta, Herrmann Richard, Maecke Helmut R, Mueller-Brand Jan, Lohri Andreas
Radiopeptide imaging and therapy in Europe
Ambrosini V, Fani M, Fanti S, Forrer F, Maecke H. Radiopeptide imaging and therapy in Europe. J Nucl Med 2011; 52 Suppl 2:42S-55S.
01.12.2011Radiopeptide imaging and therapy in Europe
01.12.2011J Nucl Med 2011; 52 Suppl 2:42S-55S
Ambrosini Valentina, Fani Melpomeni, Fanti Stefano, Forrer Flavio, Maecke Helmut R
Bombesin antagonist-based radioligands for translational nuclear imaging of gastrin-releasing peptide receptor-positive tumors
Abiraj K, Mansi R, Tamma M, Fani M, Forrer F, Nicolas G, Cescato R, Reubi J, Maecke H. Bombesin antagonist-based radioligands for translational nuclear imaging of gastrin-releasing peptide receptor-positive tumors. J Nucl Med 2011; 52:1970-8.
11.11.2011Bombesin antagonist-based radioligands for translational nuclear imaging of gastrin-releasing peptide receptor-positive tumors
11.11.2011J Nucl Med 2011; 52:1970-8
Abiraj Keelara, Mansi Rosalba, Tamma Maria-Luisa, Fani Melpomeni, Forrer Flavio, Nicolas Guillaume, Cescato Renzo, Reubi Jean Claude, Maecke Helmut R
Development of a potent DOTA-conjugated bombesin antagonist for targeting GRPr-positive tumours
Mansi R, Wang X, Forrer F, Waser B, Cescato R, Graham K, Borkowski S, Reubi J, Maecke H. Development of a potent DOTA-conjugated bombesin antagonist for targeting GRPr-positive tumours. Eur J Nucl Med Mol Imaging 2010; 38:97-107.
18.08.2010Development of a potent DOTA-conjugated bombesin antagonist for targeting GRPr-positive tumours
18.08.2010Eur J Nucl Med Mol Imaging 2010; 38:97-107
Mansi Rosalba, Wang Xuejuan, Forrer Flavio, Waser Beatrice, Cescato Renzo, Graham Keith, Borkowski Sandra, Reubi Jean Claude, Maecke Helmut R
Tetraamine-derived bifunctional chelators for technetium-99m labelling: synthesis, bioconjugation and evaluation as targeted SPECT imaging probes for GRP-receptor-positive tumours
Abiraj K, Mansi R, Tamma M, Forrer F, Cescato R, Reubi J, Akyel K, Maecke H. Tetraamine-derived bifunctional chelators for technetium-99m labelling: synthesis, bioconjugation and evaluation as targeted SPECT imaging probes for GRP-receptor-positive tumours. Chemistry 2010; 16:2115-24.
15.02.2010Tetraamine-derived bifunctional chelators for technetium-99m labelling: synthesis, bioconjugation and evaluation as targeted SPECT imaging probes for GRP-receptor-positive tumours
15.02.2010Chemistry 2010; 16:2115-24
Abiraj Keelara, Mansi Rosalba, Tamma Maria-Luisa, Forrer Flavio, Cescato Renzo, Reubi Jean Claude, Akyel Kayhan G, Maecke Helmut R
Evaluation of a 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-conjugated bombesin-based radioantagonist for the labeling with single-photon emission computed tomography, positron emission tomography, and therapeutic radionuclides
Mansi R, Wang X, Forrer F, Kneifel S, Tamma M, Waser B, Cescato R, Reubi J, Maecke H. Evaluation of a 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-conjugated bombesin-based radioantagonist for the labeling with single-photon emission computed tomography, positron emission tomography, and therapeutic radionuclides. Clin Cancer Res 2009; 15:5240-9.
11.08.2009Evaluation of a 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-conjugated bombesin-based radioantagonist for the labeling with single-photon emission computed tomography, positron emission tomography, and therapeutic radionuclides
11.08.2009Clin Cancer Res 2009; 15:5240-9
Mansi Rosalba, Wang Xuejuan, Forrer Flavio, Kneifel Stefan, Tamma Maria-Luisa, Waser Beatrice, Cescato Renzo, Reubi Jean Claude, Maecke Helmut R
In vitro characterization of (177)Lu-radiolabelled chimeric anti-CD20 monoclonal antibody and a preliminary dosimetry study
Forrer F, Chen J, Fani M, Powell P, Lohri A, Müller-Brand J, Moldenhauer G, Maecke H. In vitro characterization of (177)Lu-radiolabelled chimeric anti-CD20 monoclonal antibody and a preliminary dosimetry study. Eur J Nucl Med Mol Imaging 2009; 36:1443-52.
07.04.2009In vitro characterization of (177)Lu-radiolabelled chimeric anti-CD20 monoclonal antibody and a preliminary dosimetry study
07.04.2009Eur J Nucl Med Mol Imaging 2009; 36:1443-52
Forrer Flavio, Chen Jianhua, Fani Melpomeni, Powell Pia, Lohri Andreas, Müller-Brand Jan, Moldenhauer Gerhard, Maecke Helmut R
Targeted radionuclide therapy with 90Y-DOTATOC in patients with neuroendocrine tumors
Forrer F, Waldherr C, Maecke H, Mueller-Brand J. Targeted radionuclide therapy with 90Y-DOTATOC in patients with neuroendocrine tumors. Anticancer Res 2006; 26:703-7.
01.01.2006Targeted radionuclide therapy with 90Y-DOTATOC in patients with neuroendocrine tumors
01.01.2006Anticancer Res 2006; 26:703-7
Forrer Flavio, Waldherr Christian, Maecke Helmut R, Mueller-Brand Jan
Treatment with 177Lu-DOTATOC of patients with relapse of neuroendocrine tumors after treatment with 90Y-DOTATOC
Forrer F, Uusijärvi H, Storch D, Maecke H, Mueller-Brand J. Treatment with 177Lu-DOTATOC of patients with relapse of neuroendocrine tumors after treatment with 90Y-DOTATOC. J Nucl Med 2005; 46:1310-6.
01.08.2005Treatment with 177Lu-DOTATOC of patients with relapse of neuroendocrine tumors after treatment with 90Y-DOTATOC
01.08.2005J Nucl Med 2005; 46:1310-6
Forrer Flavio, Uusijärvi Helena, Storch Daniel, Maecke Helmut R, Mueller-Brand Jan